Archives | LinksMedicus Free Medical News & Perspectives

EMA recommends approval of Pfizer-BioNTech vaccine for children aged 5 to 11.

26 Nov, 2021 | 08:47h | UTC

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 – European Medicines Agency

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

What COVID vaccines for young kids could mean for the pandemic.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

Commentary on Twitter

‼️ EMA recommends approval of BioNTech/Pfizer’s #COVID19vaccine, Comirnaty, for children aged 5 to 11.

In this population, the dose of #Comirnaty will be lower than that used in people aged 12 and above.

Read the full press release: https://t.co/uqqBAklVvl pic.twitter.com/NZQhli4SDl

— EU Medicines Agency (@EMA_News) November 25, 2021

Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.

26 Nov, 2021 | 08:42h | UTC

Heavily mutated coronavirus variant puts scientists on alert – Nature

Review: Prevention and management of thrombosis in hospitalized patients with COVID-19 pneumonia.

26 Nov, 2021 | 08:44h | UTC

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia – The Lancet Respiratory Medicine

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

26 Nov, 2021 | 08:35h | UTC

Persistent symptoms following SARS-CoV-2 infection among children and young people: a meta-analysis of controlled and uncontrolled studies – Journal of Infection

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

M-A: Comparing the clinical efficacy of COVID-19 vaccines.

26 Nov, 2021 | 08:37h | UTC

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis – Scientific Reports

[Preprint] Serological responses to COVID-19 booster vaccine in England.

26 Nov, 2021 | 08:34h | UTC

Serological responses to COVID-19 booster vaccine in England – medRxiv

Commentary from the author on Twitter (thread – click for more)

1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … 🧵

👉 https://t.co/JYxwH4JM51

— Shamez Ladhani (@ShamezLadhani) November 25, 2021

WHO Interim statement on COVID-19 vaccination for children and adolescents.

25 Nov, 2021 | 10:49h | UTC

Interim statement on COVID-19 vaccination for children and adolescents – World Health Organization

Perspective: COVID-19 vaccine makers plan for annual boosters, but it’s not clear they’ll be needed.

25 Nov, 2021 | 10:43h | UTC

COVID-19 Vaccine Makers Plan for Annual Boosters, but It’s Not Clear They’ll Be Needed – JAMA

COVID-19 reinfection: the role of natural immunity, vaccines, and variants.

25 Nov, 2021 | 10:45h | UTC

COVID-19 reinfection: the role of natural immunity, vaccines, and variants – Journal of Community Hospital Internal Medicine Perspectives

Do vaccines protect against long COVID? What the data say – “Vaccines reduce the risk of developing COVID-19 — but studies disagree on their protective effect against long COVID”.

25 Nov, 2021 | 10:41h | UTC

Do vaccines protect against long COVID? What the data say – Nature

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Commentary on Twitter

Vaccines reduce the risk of long COVID by lowering the chances of contracting COVID-19. But studies suggest that vaccination might only halve the risk of long COVID, or have no effect on it at all, in a breakthrough infection. Read the @Nature report. https://t.co/MEkzXyO7hD

— Nature Portfolio (@NaturePortfolio) November 25, 2021

Cuba’s bet on home-grown COVID vaccines is paying off.

25 Nov, 2021 | 10:39h | UTC

Cuba’s bet on home-grown COVID vaccines is paying off – Nature

A population-based cohort study in Qatar showed reinfections had 90% lower odds of resulting in hospitalization or death than primary infections.

25 Nov, 2021 | 10:46h | UTC

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections – New England Journal of Medicine

ACSM Expert Consensus Statement: Injury prevention and exercise performance during cold-weather exercise.

25 Nov, 2021 | 10:29h | UTC

ACSM Expert Consensus Statement: Injury Prevention and Exercise Performance during Cold-Weather Exercise – Current Sports Medicine Reports

WHO releases HIV drug resistance report 2021.

25 Nov, 2021 | 10:36h | UTC

News Release: WHO releases HIV drug resistance report 2021 – World Health Organization

Report: HIV drug resistance report 2021 – World Health Organization

Fact Sheet: HIV Drug Resistance – World Health Organization

Commentary on Twitter

🆕 Check out WHO’s latest HIV Drug Resistance Report & find out:

💊 how drug resistance is growing
💊 steps countries are taking to ensure people will receive effective medicine to treat & prevent HIVhttps://t.co/76teEHFrVV

— World Health Organization (WHO) (@WHO) November 24, 2021

Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children.

25 Nov, 2021 | 10:31h | UTC

Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children – British Journal of Haematology

Global epidemiology of stroke and access to acute ischemic stroke interventions.

25 Nov, 2021 | 10:27h | UTC

Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions – Neurology

Promises and challenges of personalized medicine to guide ARDS therapy.

25 Nov, 2021 | 10:25h | UTC

Promises and challenges of personalized medicine to guide ARDS therapy – Critical Care

Systematic Review: Macrolides versus placebo for chronic asthma.

25 Nov, 2021 | 10:14h | UTC

Macrolides versus placebo for chronic asthma – Cochrane Library

Commentary on Twitter

Graphical abstract for #Cochrane Review on #Macrolides versus placebo for chronic #asthma Full review here https://t.co/SrHacxWoNr pic.twitter.com/0YCd9Xptlz

— CochraneAirways (@CochraneAirways) November 24, 2021